Randomized Trial of the Combination of Lomeguatrib and Temozolomide Compared With Temozolomide Alone in Chemotherapy Naive Patients With Metastatic Cutaneous Melanoma

Journal of Clinical Oncology - United States
doi 10.1200/jco.2007.10.8217
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society of Clinical Oncology (ASCO)

Related search

Chemotherapy of Metastatic Neuroendocrine Tumors With Aranose in Monoregimen and in Combination With Capecitabine and Temozolomide.

Malignant tumours
2015English

Chemotherapy-Associated Steatohepatitis With Temozolomide and Dexamethasone

Canadian Journal of Neurological Sciences
MedicineNeurology
2012English

A Phase I/Ii Study of Lomustine and Temozolomide in Patients With Cerebral Metastases From Malignant Melanoma

British Journal of Cancer
Cancer ResearchOncology
2006English

The Addition of Cixutumumab or Temozolomide to Intensive Multiagent Chemotherapy Is Feasible but Does Not Improve Outcome for Patients With Metastatic Rhabdomyosarcoma

Cancer
Cancer ResearchOncology
2018English

Dasatinib-Induced Autophagy Is Enhanced in Combination With Temozolomide in Glioma

Molecular Cancer Therapeutics
Cancer ResearchOncology
2009English

Short-Course Radiation Plus Temozolomide in Elderly Patients With Glioblastoma

New England Journal of Medicine
Medicine
2017English

Pcn220 - End-Of-Life Care in Patients With Metastatic Cutaneous Melanoma in the Netherlands

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Phase II, Multicenter, Randomized Trial of Docetaxel Plus Prednisone With or Without Cediranib in Men With Chemotherapy‐Naive Metastatic Castrate‐Resistant Prostate Cancer

Oncologist
Cancer ResearchMedicineOncology
2019English

Inhibition of Telomerase Increases Resistance of Melanoma Cells to Temozolomide, but Not to Temozolomide Combined With Poly (ADP-Ribose) Polymerase Inhibitor

Molecular Pharmacology
Molecular MedicinePharmacology
2003English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy